tm
Seeing Is Believing
tm
Seeing Is Believing
NAMS is currently covered by 7 analysts with an average price target of $47.21. This is a potential upside of $16.26 (109.92%) from yesterday's end of day stock price of $22.49.
NewAmsterdam Pharma Company N.V. Ordinary Shares's activity chart (see below) currently has 50 price targets and 46 ratings on display. The stock rating distribution of NAMS is 90.91% BUY and 9.09% HOLD.
Analysts average stock forecasts to be materialized ratio is 41% with an average time for these price targets to be met of 214.5 days.
Highest price target for NAMS is $52, Lowest price target is $37, average price target is $47.21.
Most recent stock forecast was given by LEONID TIMASHEV from RBC on 06-Aug-2026. First documented stock forecast 18-Dec-2022.
Currently out of the existing stock ratings of NAMS, 10 are a BUY (90.91%), 1 are a HOLD (9.09%).
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date of last PT
Price targets met ratio
Average potential upside
Average Days to Hit Target
Performance score
Buy Since 30-Oct-2023
$50
$27.51 (122.32%)
$51
1 months 14 days ago
(06-Aug-2026)
7/11 (63.64%)
$22.33 (80.70%)
378
Buy Since 18-Jan-2024
$45
$11.76 (35.38%)
$30
7 months 1 days ago
(19-Feb-2026)
1/2 (50%)
$10.37 (29.95%)
623
Buy Since 28-Aug-2024
$48
$14.76 (44.40%)
$40
7 months 2 days ago
(18-Feb-2026)
7/10 (70%)
$12.24 (34.23%)
285
Buy Since 10-Jun-2025
$50
$16.76 (50.42%)
9 months 4 days ago
(16-Dec-2025)
0/2 (0%)
$15.78 (46.11%)
Hold Since 17-Jul-2025
$37
$3.76 (11.31%)
$27
9 months 18 days ago
(02-Dec-2025)
2/2 (100%)
$-1.33 (-3.47%)
26
What is NAMS (NewAmsterdam Pharma Company N.V. Ordinary Shares) average time for price targets to be met?
Which analyst most recently updated their price target on NAMS (NewAmsterdam Pharma Company N.V. Ordinary Shares)?
Which analyst has the most public recommendations on NAMS (NewAmsterdam Pharma Company N.V. Ordinary Shares)?
Which analyst is the currently most bullish on NAMS (NewAmsterdam Pharma Company N.V. Ordinary Shares)?
Which analyst is the currently most reserved on NAMS (NewAmsterdam Pharma Company N.V. Ordinary Shares)?
